12:00 AM
 | 
Dec 11, 2000
 |  BC Week In Review  |  Company News  |  Deals

Encore, Myriad Genetics deal

MYGN acquired exclusive worldwide rights from Encore to E-7869 (renamed MPC-7869), a daily oral compound that has completed Phase IIa trials to treat...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >